Trial Profile
Maraviroc as an Immunomodulatory Drug for Antiretroviral-Treated HIV Infected Patients Exhibiting Immunologic Failure.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Pharmacodynamics; Therapeutic Use
- 17 Jul 2012 Actual initiation date changed from Aug 2008 to Sep 2008 as reported by ClinicalTrials.gov.
- 17 Jul 2012 Actual end date Jul 2010 added as reported by ClinicalTrials.gov.
- 01 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.